Which has stronger earnings and valuation, ORKA or CAPR?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A

Is ORKA or CAPR more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% Capricor Therapeutics N/A -59.27% -48.65%

Which has higher valuation & earnings, MANE or CAPR?

Veradermics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A -$1.32 N/A Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A

Is MANE or CAPR more profitable?

Veradermics' return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Capricor Therapeutics N/A -59.27% -48.65%

Capricor Therapeutics (CAPR) Competitors

$19.50 +0.06 (+0.31%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$19.65 +0.15 (+0.75%)

As of 04:00 AM Eastern

Compare

CAPR vs. DNTH, ORKA, MANE, GRFS, and INDV

Should you buy Capricor Therapeutics stock or one of its competitors? MarketBeat compares Capricor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capricor Therapeutics include Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), Veradermics (MANE), Grifols (GRFS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Capricor Therapeutics compare to Dianthus Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Capricor Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Dianthus Therapeutics	$2.04M	2,706.70	-$162.34M	-$4.13	N/A

Capricor Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Capricor Therapeutics currently has a consensus price target of $53.67, indicating a potential upside of 175.21%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 16.65%. Given Capricor Therapeutics' higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 4 mentions for Dianthus Therapeutics and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 0.33 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capricor Therapeutics	Positive
Dianthus Therapeutics	Neutral

Summary

Dianthus Therapeutics beats Capricor Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Capricor Therapeutics. MarketBeat recorded 3 mentions for Oruka Therapeutics and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Oruka Therapeutics' score of 0.50 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oruka Therapeutics	Positive
Capricor Therapeutics	Positive

Oruka Therapeutics presently has a consensus target price of $134.30, suggesting a potential upside of 46.44%. Capricor Therapeutics has a consensus target price of $53.67, suggesting a potential upside of 175.21%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Oruka Therapeutics' return on equity of -26.16% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Oruka Therapeutics has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Summary

Oruka Therapeutics and Capricor Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Veradermics?

Veradermics (NYSE:MANE) and Capricor Therapeutics (NASDAQ:CAPR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Veradermics' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Capricor Therapeutics	N/A	-59.27%	-48.65%

Veradermics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Veradermics presently has a consensus price target of $153.00, indicating a potential upside of 43.13%. Capricor Therapeutics has a consensus price target of $53.67, indicating a potential upside of 175.21%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Veradermics had 20 more articles in the media than Capricor Therapeutics. MarketBeat recorded 20 mentions for Veradermics and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Veradermics' score of 0.45 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
Capricor Therapeutics	Positive

Summary

Capricor Therapeutics beats Veradermics on 8 of the 12 factors compared between the two stocks.

How does Capricor Therapeutics compare to Grifols?

Capricor Therapeutics (NASDAQ:CAPR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Capricor Therapeutics currently has a consensus price target of $53.67, suggesting a potential upside of 175.21%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 31.41%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Grifols had 1 more articles in the media than Capricor Therapeutics. MarketBeat recorded 1 mentions for Grifols and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Grifols' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capricor Therapeutics	Positive
Grifols	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Capricor Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Capricor Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Grifols	5.54%	6.21%	2.39%

Grifols has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.05

Summary

Grifols beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Indivior?

Capricor Therapeutics (NASDAQ:CAPR) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Capricor Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, Indivior had 2 more articles in the media than Capricor Therapeutics. MarketBeat recorded 2 mentions for Indivior and 0 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Indivior's score of 0.42 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capricor Therapeutics	Positive
Indivior	Neutral

Indivior has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Indivior	$1.24B	3.85	$210M	$1.95	20.06

Indivior has a net margin of 19.44% compared to Capricor Therapeutics' net margin of 0.00%. Capricor Therapeutics' return on equity of -59.27% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Indivior	19.44%	-219.26%	29.40%

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics presently has a consensus target price of $53.67, indicating a potential upside of 175.21%. Indivior has a consensus target price of $40.29, indicating a potential upside of 2.98%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Indivior beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.13B	$8.90B	$6.89B	$12.28B
Dividend Yield	N/A	2.48%	2.67%	9.39%
P/E Ratio	-8.41	16.04	27.07	23.94
Price / Sales	N/A	6.77	515.45	90.30
Price / Cash	N/A	18.55	26.68	47.25
Price / Book	3.53	3.26	10.42	6.14
Net Income	-$105.04M	$230.22M	$3.60B	$331.74M
7 Day Performance	-5.71%	-1.77%	-1.26%	-1.81%
1 Month Performance	-31.29%	-1.97%	1.07%	-1.44%
1 Year Performance	211.00%	-0.92%	23.61%	16.33%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.8667 of 5 stars	$19.50 +0.3%	$53.67 +175.2%	+183.4%	$1.13B	N/A	N/A	101	Positive News
DNTH Dianthus Therapeutics	1.9506 of 5 stars	$95.76 +2.6%	$117.82 +23.0%	+395.1%	$5.10B	$2.04M	N/A	80
ORKA Oruka Therapeutics	2.9457 of 5 stars	$84.50 +1.6%	$134.30 +58.9%	+530.7%	$5.01B	N/A	N/A	N/A
MANE Veradermics	3.1316 of 5 stars	$117.24 -4.0%	$135.60 +15.7%	N/A	$4.90B	N/A	N/A	19
GRFS Grifols	4.02 of 5 stars	$7.21 +0.6%	$10.00 +38.7%	-23.4%	$4.88B	$7.44B	37.95	25,247	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. DNTH, ORKA, MANE, GRFS, and INDV

How does Capricor Therapeutics compare to Dianthus Therapeutics?

Summary

How does Capricor Therapeutics compare to Oruka Therapeutics?

Summary

How does Capricor Therapeutics compare to Veradermics?

Summary

How does Capricor Therapeutics compare to Grifols?

Summary

How does Capricor Therapeutics compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. DNTH, ORKA, MANE, GRFS, and INDV

How does Capricor Therapeutics compare to Dianthus Therapeutics?

Which has preferable valuation & earnings, CAPR or DNTH?

Is CAPR or DNTH more profitable?

Do analysts rate CAPR or DNTH?

Do insiders and institutionals have more ownership in CAPR or DNTH?

Which has more volatility & risk, CAPR or DNTH?

Does the media refer more to CAPR or DNTH?

Summary

How does Capricor Therapeutics compare to Oruka Therapeutics?

Does the media prefer ORKA or CAPR?

Do analysts recommend ORKA or CAPR?

Is ORKA or CAPR more profitable?

Which has more risk & volatility, ORKA or CAPR?

Do insiders and institutionals hold more shares of ORKA or CAPR?

Which has stronger earnings and valuation, ORKA or CAPR?

Summary

How does Capricor Therapeutics compare to Veradermics?

Is MANE or CAPR more profitable?

Which has higher valuation & earnings, MANE or CAPR?

Do analysts recommend MANE or CAPR?

Do insiders & institutionals believe in MANE or CAPR?

Does the media favor MANE or CAPR?

Summary

How does Capricor Therapeutics compare to Grifols?

Do analysts prefer CAPR or GRFS?

Does the media favor CAPR or GRFS?

Do institutionals & insiders hold more shares of CAPR or GRFS?

Which has more risk & volatility, CAPR or GRFS?

Is CAPR or GRFS more profitable?

Which has preferable valuation & earnings, CAPR or GRFS?

Summary

How does Capricor Therapeutics compare to Indivior?

Which has more risk & volatility, CAPR or INDV?

Does the media refer more to CAPR or INDV?

Which has higher valuation and earnings, CAPR or INDV?

Is CAPR or INDV more profitable?

Do institutionals and insiders have more ownership in CAPR or INDV?

Do analysts rate CAPR or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools